Last update: June 1, 2017
Minimal risk for breastfeeding and infant.
Since the last update we have not found published data regarding breastfeeding, but its pharmacokinetic characteristics (low systemic absorption, moderately elevated molecular weight, high plasma protein binding and large volume of distribution, AEMPS 2014, FDA 2012) make it very unlikely its excretion into breast milk in significant amounts and its subsequent absorption by the infant.
At normal doses it is very rarely absorbed orally or via inhalation (nasal or pulmonary), and does not reach significant levels in plasma (FDA 2012).
Experts in breastfeeding and medication consider topical, oral or inhaled corticosteroids to be compatible with breastfeeding (National Asthma Education 2004, Ellsworth 1994, Greenberger 1987).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM